De Novo
DEN230051: Myocene
FDA De Novo · myocene · decided Jan 17, 2025
Key facts
| De Novo number | DEN230051 |
|---|---|
| Device name | Myocene |
| Applicant | myocene |
| Product code | SDX |
| Date received | Jul 27, 2023 |
| Decision date | Jan 17, 2025 |
| Decision | granted (DENG) |
| FDA classification | Class II |
| Review panel | Neurology |
| FEI number | 3036833452 |
At a glance
- None Later 510(k)s citing this De Novo
- 1–9 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
- No Decision summary on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About De Novo classification requests
The De Novo pathway classifies novel low- to moderate-risk devices that have no legally marketed predicate; each granted request creates a new classification regulation and product code.
Source: U.S. Food and Drug Administration (FDA), De Novo database · Source date: